10 Devices that Could Pose Problems for Patients with ICDs

Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

The Tina-quant® Lipoprotein (a) Gen.2 Molarity assay measures Lp(a) in molar units, providing a more accurate particle-based risk assessment than mass units.

Data set to be presented at ISC 2025 shows that the protective effect of propranolol was stronger for ischemic stroke compared to other stroke types.